PTO/S8/05a (01-10)

Approved for use through 07/31/2012 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contrains a valid OMB control number

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 GFR 1.99)	Application Number		10596817		
	Filing Date		2007-03-01		
	First Named Inventor	Jonat	athan David CASTILE		
	Art Unit		1616		
	Examiner Name	M, Ha	aghighatian	Ξ	
	Attorney Docket Numb	er	10774-87US(ARCCX/P32302US		

II S DATENTS

					0.0.	71121110				,	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	1 Issue Date		Name of Par of cited Doc	Releva		Lines where ges or Relev		
	1	7423026		2008-09	1-09	Jarvinen et al					
	2	6713461		2004-03	1-30	Billotte					
If you wisi	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	1	_
Examiner Initial*	Cite No Publication Number		Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines who Relevant Passages or Re Figures Appear			
If you wisi	1 h to ad	d additional U.S. Pub	lished Ap	plication	n citatio	n information	please click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	MENTS		Remove		_
Examiner Cite Foreign Document Number3		Country Code ² j		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or where R		or Relevant	TE	
	1										
If you wis	h to ad	ld additional Foreign F	atent Do	cument	citation	information p	lease click the Add	button	Add		_
		-	NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove	İ	_

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

	1	MERKUS et al., "Cyclodextrins in Nasel Drug Delivery", Advanced Drug Delivery Reviews, 36th Edition, pp. 41-57, (1999).	
	2	ILLUM, "NASEL DELIVERY. THE USE OF ANIMAL MODELS TO PREDICT PERFORMANCE IN MAN"; Journal of Drug Targeting, Vol. 3, pp. 427-442 (1996).	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

publisher, city and/or country where published.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kint Code of USPTO Patent Documents at twent USPTO.GOV or MPEP 901.04. Enter of tions that issued the document, by the hor-left or killed (WIPO) Standard 91.3.) For Lapraenee patent counters, the inclusion of the parent of the improve many precise the serial results of the patent document.

1 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 91.16 if possible. Spipicant is to place a check mank here if Employin languages the resiliation is attached.

Examiner Cite

Initials* No.